Quadruple‐hit Pleomorphic Mantle Cell Lymphoma with MYC, BCL2, BCL6, and CCND1 Gene Rearrangements
Wei Liu,Xiaoqian Chen,Jianlin Fan,Mingqing Zhu,Hongjie Shen,Xiaochen Chen,Guanghua Chen,Yu Duan,Bin He,Zhao Zeng,Depei Wu,Jinlan Pan,Haiwen Huang
DOI: https://doi.org/10.1111/bjh.17729
2021-01-01
British Journal of Haematology
Abstract:B-cell lymphomas that concurrently carry MYC, BCL2 and/or BCL6 gene rearrangements – so-called double-hit or triple-hit lymphomas – are rare entities associated with poor prognosis. B-cell lymphomas with translocations involving MYC, BCL2, BCL6 and CCND1 genes (quadruple-hit) are extremely rare, with limited cases reported to date.1-3 Herein we report a case diagnosed at an early stage and remaining disease-free for 15 months after the initial diagnosis. This study was approved by the Institutional Review Board of the First Affiliated Hospital of Soochow University. Written informed consent was obtained from the patient. The patient was a 76-year-old man suffering from pharyngeal obstruction for 2 months. A positron emission tomography scan showed multiple cervical lymphadenopathies (Fig 1A). The laboratory tests were unremarkable including a normal serum lactate dehydrogenase (LDH) level. Biopsy of the left cervical lymph node displayed effaced architecture by a diffuse infiltrate of medium to large lymphocytes. Tangible body macrophages were observed at lower magnification. At higher magnification, the tumour cells revealed a moderate amount of cytoplasm, round or slightly irregular nuclei, moderately dispersed chromatin and one or more small and occasionally prominent nucleoli (Fig 2A). By flow-cytometric immunophenotyping, 58·4% of the gated lymphoid events revealed a kappa immunoglobulin light chain restriction. These cells expressed pan-B markers such as CD19, CD20, and FMC7 with weak CD23 positivity. CD200, CD79b, CD5 and 10 were negative. By immunohistochemical (IHC) staining, the lymphoma cells were positive for CD20, CD79a, BCL6, cyclin D1, CD21, BCL2 and MYC. P53 was positive in occasional cells (Fig 2B–H). The Ki67 proliferative rate was 60% (Fig 2I). The tumour cells were negative for CD3, CD5, SOX11, MUM1, and EBER by in situ hybridisation. Examination of the bone marrow biopsy showed it to be negative for tumour infiltration. Given the over-expression of BCL6, MYC, cyclin D1, and BCL2, interphase fluorescence in situ hybridisation (FISH) analyses of these relevant genes were performed. Dual-color dual-fusion (D-FISH) probes (Beijing Jinpujia Medical Technologies, Beijing, China) were selected for MYC-IGH, CCND1-IGH and IHG-BCL2 rearrangements. In addition, a break-apart probe (BAP; Beijing Jinpujia Medical Technologies) was used for BCL6 rearrangement. The FISH analyses were performed on 4 μm paraffin-embedded tissue sections and it was considered positive if more than 15% of the tumour cells exhibited a fusion or break-apart signal. D-FISH of IGH-MYC (Fig 2J), IGH-CCND1 (Fig 2K) and IGH-BCL2 (Fig 2L) showed one fusion signal in 34% of 100 suspension cells, indicating MYC-IGH, CCND1-IGH and IGH-BCL2 rearrangements. Similarly, a BCL6 (Fig 2M) break was detected in 38% of 100 suspension cells, suggesting translocations of the genes. The FISH analyses were also repeated on tissue sections. Moreover, FISH analyses using BAP (Abbott Molecular, Des Plaines, IL, USA) of BCL2 (Figure S1A) and CCND1 (Figure S1B) revealed split signals on tissue sections, demonstrating a break of both genes. Therefore, according to the morphology, immunophenotype and FISH results, a final diagnosis of quadruple-hit pleomorphic mantle cell lymphoma (MCL) was favoured. Cytogenetic analysis was failed due to a lack of growth of metaphase cells after a short term of cell culture. However, we were able to perform Cytoscan 750k (Affymetrix, Santa Clara, CA, USA) single nucleotide polymorphism microarray (SNP-array) assay to assess genome-wide chromosomal copy number aberrations (CNAs). The SNP-array revealed apparent gains of whole chromosomes X, Y, 5 and 7, as well as segmental gains of chromosomes 1p36p23, 1q23q25, 1q25q31, 1q31q32, 1q41q42, 1q42q44, 2p25p16, 2p12p11, 2p11q12, 3p26q27, 6p25p12, 17q12q24, and 21q11q22 (Fig 2N). The genome-wide CNA pattern was suggestive for the presence of a complex hyperdiploid clone, with evidence of a chromothripsis-like pattern of 1q. Additionally, next-generation sequencing (NGS) was performed for somatic mutations with a targeted panel covering 222 genes, with an average sequencing depth of more than 1000 times. NGS revealed 12 nonsynonymous single nucleotide variants, one frameshift mutation, and one nonsense mutation, involving ARID1B, BCL2 (3), CCND1 (3), FOXO1, IL7R, MGA, PIM1 and SGK1 (3) genes (Table SI). No mutation was identified in the TP53 gene, which was consistent with IHC results. Deletions or mutations of the ARID1B gene have been observed in lymphoplasmacytic lymphoma.4 The Y24I mutation in FOXO1 gene has been identified in diffuse large B-cell lymphoma (DLBCL) and was associated with decreased overall survival.5 Mutations of the SGK1 gene were common in DLBCL and the PIMI gene mutation has been identified in DLBCL (leg type) and multiple myeloma.6 Interestingly, multiple mutations of BCL2 and CCND1 genes were also identified, which have rarely been reported to be co-existing with gene rearrangements. Of note, the CCND1 mutations have been reported in MCL.7 On the other hand, mutations in IL7R and MGA genes were not identified in the literature and the functional consequence remains unknown. Our patient received six cycles of lenalidomide in combination with R2-CHOP (one cycle standard R-CHOP on days 1–5, and 25 mg oral lenalidomide per day on days 1–14). He achieved complete remission after four cycles (Fig 1B) and was disease-free 15 months after initial diagnosis. Quadruple-hit lymphoma is rare and associated with a dismal prognosis.1-3 The prognosis of our patient was relatively good, and this may be due to an early-stage diagnosis, normal LDH level, and negative TP53 mutation.8 To further characterise the prognosis of our patient, MCL international prognostic index (MIPI) and biological MIPI (MIPIb) were evaluated, as described previously.9, 10 The patient was classified as high risk, both for the MIPI and MIPIb scores, with a predicted overall survival of 37 months. Thus, a longer follow-up is warranted to evaluate the clinical outcome. MYC gene rearrangement in MCL is rare, with limited cases reported to date.10-15 It was found to be associated with a higher median white blood cell, blastoid/pleomorphic morphology, medium-high MIPI risk and shorter overall survival.12, 15 Of note, these cases of quadruple-hit lymphoma showed high grade histological features. Therefore, testing of MYC protein in blastoid/pleomorphic MCL may help to identify those carry additional MYC gene rearrangements, and even quadruple-hit lymphomas. More cases with detailed clinical-pathological and biological data are needed to better characterise this entity. The authors would like to thank Sicheng Ai (New York University, New York, NY, 10003, USA) for his help in the preparation of the manuscript. WL, XC and JF designed the study and wrote the manuscript; MZ performed flow cytometric analysis; HS performed and analysed the next generation sequencing; XC and DW was involved in the clinical part and follow-up of the patient; GC performed the cytological analysis; YD and BH provided clinical data; ZZ and JP performed cytogenetic analysis; HH supervised the study and wrote the manuscript. This work was supported by grants from the Postdoctoral Science Foundation of Jiangsu Province (No. 1402080B), Translational Research Grant of NCRCH (No. 2020ZKMB02) and Suzhou Science and Technology Development Projects (No. SYS2019039 and SYSD2020104). The authors declare no relevant conflict of interest. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.